Is a patent foramen ovale (PFO) in a patient with systemic lupus erythematosus (SLE) who develops dengue infection rare, what is its approximate prevalence, and is there a pathophysiologic relationship?

Patent Foramen Ovale in SLE Triggered by Dengue: Rarity and Relationship

Patent foramen ovale (PFO) itself is not rare—it occurs in approximately 25% of the general population 1, 2—but the specific scenario of PFO in an SLE patient with dengue-triggered disease manifestations represents an exceptionally uncommon clinical presentation with limited documented cases.

Prevalence Context

The baseline prevalence of PFO is well-established:

• 25% of all adults have a PFO 1, 2
• This represents a common congenital variant where the foramen ovale fails to close after birth
• PFO prevalence increases to approximately 50% in patients under 60 years with cryptogenic stroke 1

However, the intersection of PFO with SLE and dengue infection is extraordinarily rare, with only isolated case reports in the medical literature.

Pathophysiologic Relationship

There is a plausible mechanistic connection between these three conditions:

SLE and Thromboembolism

• SLE patients have significantly elevated thrombotic risk due to antiphospholipid antibodies, endothelial dysfunction, and chronic inflammation
• One documented case 3 showed a thromboembolus actively traversing a PFO in a 72-year-old man with SLE and dilated cardiomyopathy, demonstrating the potential for paradoxical embolism in this population

Dengue as a Trigger

• Dengue infection can trigger lupus flares through immunological activation 4
• A recent case 4 documented a 39-year-old female with dengue-induced pancarditis (affecting all cardiac layers) in the setting of active SLE
• Dengue causes thrombocytopenia, endothelial dysfunction, and a hypercoagulable state during recovery, potentially increasing paradoxical embolism risk through a PFO

The Mechanistic Pathway

The proposed relationship involves:

1. Dengue triggers SLE flare → increased systemic inflammation and autoantibody production
2. SLE-associated hypercoagulability → venous thrombosis formation
3. PFO provides anatomical substrate → right-to-left shunting allows paradoxical embolism 5, 6
4. Dengue-induced thrombocytopenia paradoxically increases thrombotic risk during recovery phase

Clinical Implications

When to Suspect This Combination

• Young SLE patients presenting with neurological events (stroke/TIA) during or after dengue infection
• Unexplained systemic embolic phenomena in SLE patients with recent dengue
• Paradoxical embolism in the setting of dengue-triggered lupus flare

Diagnostic Approach

• Bubble contrast echocardiography (transthoracic or transesophageal) to detect and quantify right-to-left shunting 7
• Assess for high-risk PFO features: large shunt (>10mm), atrial septal aneurysm, prominent Eustachian valve 1, 2
• Evaluate for concurrent deep vein thrombosis as embolic source
• Screen for antiphospholipid antibodies if not previously done

Management Considerations

While guidelines 8, 9 focus on cryptogenic stroke populations, they do not specifically address SLE or dengue contexts. However:

• Anticoagulation is likely preferred over antiplatelet therapy in SLE patients with PFO and thrombotic events, given the underlying hypercoagulable state
• PFO closure should be considered only after careful risk-benefit analysis, as SLE patients may have increased procedural risks
• The primary focus should be on controlling SLE disease activity and managing the acute dengue infection

Critical Caveats

• The specific combination you describe is not systematically studied—evidence is limited to isolated case reports
• Do not assume PFO is causative simply because it's present; 1 in 4 people have a PFO incidentally
• Dengue-induced thrombocytopenia may complicate anticoagulation decisions during acute infection
• Correlation does not equal causation: the PFO may be an incidental finding rather than pathophysiologically relevant to the clinical presentation

The rarity of this specific clinical scenario means management must be individualized based on the dominant pathology (SLE activity vs. dengue complications vs. thromboembolic risk), with PFO management guided by established cryptogenic stroke principles when embolic events occur 8, 1.